JP2013516425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516425A5 JP2013516425A5 JP2012547305A JP2012547305A JP2013516425A5 JP 2013516425 A5 JP2013516425 A5 JP 2013516425A5 JP 2012547305 A JP2012547305 A JP 2012547305A JP 2012547305 A JP2012547305 A JP 2012547305A JP 2013516425 A5 JP2013516425 A5 JP 2013516425A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- revascularization
- administration
- vascular occlusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 230000000250 revascularization Effects 0.000 claims 18
- 206010053648 Vascular occlusion Diseases 0.000 claims 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000000271 cardiovascular Effects 0.000 claims 2
- 201000006233 congestive heart failure Diseases 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229960000103 thrombolytic agents Drugs 0.000 claims 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 claims 1
- 108010082834 Brain Natriuretic Peptide Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 claims 1
- 229940012957 Plasmin Drugs 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 208000006117 ST Elevation Myocardial Infarction Diseases 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 229960005202 Streptokinase Drugs 0.000 claims 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 1
- 229960005356 Urokinase Drugs 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 230000003073 embolic Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002440 hepatic Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 201000007272 intracranial sinus thrombosis Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 230000000896 plasminic Effects 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108010073863 saruplase Proteins 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 108010008962 streptokinase-plasminogen complex Proteins 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
Claims (22)
- 血管閉塞傷害を治療するための、D−Arg−2'6'−Dmt−Lys−Phe−NH2ペプチド、またはその薬学的に許容される塩を含む、医薬組成物。
- 血行再建術前に投与するための、請求項1に記載の医薬組成物。
- 血行再建術後に投与するための、請求項1に記載の医薬組成物。
- 血行再建術中および血行再建術後に投与するための、請求項1に記載の医薬組成物。
- 血行再建術前、血行再建術中、および血行再建術後に連続して投与するための、請求項1に記載の医薬組成物。
- 血行再建術後に少なくとも3時間の間投与するための、請求項5に記載の医薬組成物。
- 血行再建術の約1時間前から投与するための、請求項5に記載の医薬組成物。
- 血行再建術の約30分前から投与するための、請求項5に記載の医薬組成物。
- 心筋梗塞に罹患している対象に投与するための、請求項1に記載の医薬組成物。
- ST上昇型心筋梗塞または非ST上昇型心筋梗塞に罹患している対象に投与するための、請求項1に記載の医薬組成物。
- 血管形成を必要としている対象に投与するための、請求項1に記載の医薬組成物。
- バルーン血管形成、ステントの挿入、経皮経管冠動脈形成、または方向性冠動脈粥腫切除から成る群から選択される血行再建術を受ける、受けている又は受けた患者に投与するための、請求項1に記載の医薬組成物。
- 閉塞の除去を受ける又は受けた患者に投与するための、請求項1に記載の医薬組成物。
- 1つまたは複数の血栓溶解剤の投与を含む血行再建術を受ける、受けている又は受けた対象に投与するための、請求項1に記載の医薬組成物。
- 1つまたは複数の血栓溶解剤が、組織プラスミノーゲン活性化因子、ウロキナーゼ、プロウロキナーゼ、ストレプトキナーゼ、プラスミノーゲンのアシル化型、プラスミンのアシル化型、およびアシル化ストレプトキナーゼ−プラスミノーゲン複合体から成る群から選択される、請求項14に記載の医薬組成物。
- 血管閉塞が心臓血管閉塞である、請求項1に記載の医薬組成物。
- 血管閉塞が頭蓋内血管閉塞である、請求項1に記載の医薬組成物。
- 血管閉塞が腎血管閉塞である、請求項1に記載の医薬組成物。
- 血管閉塞が、深部静脈血栓症、抹消血栓症、塞栓性血栓症、肝静脈血栓症、静脈洞血栓症、静脈血栓症、閉塞した動静脈短絡、および閉塞したカテーテルデバイスから成る群から選択される、請求項1に記載の医薬組成物。
- CK−MB、トロポニン、N末端プロ脳性ナトリウム利尿ペプチド(NT−proBNP)、グルコース、および推算糸球体濾過量(eGFR)のうちの1つまたは複数のレベルが、血行再建術を受けたが請求項1に記載の医薬組成物が投与されていない比較対象に対して、前記医薬組成物が投与された対象において減少する、請求項1に記載の医薬組成物。
- 血行再建術後の入院中の再梗塞、鬱血性心不全、反復血行再建術、腎不全、または死亡の発生率が、血行再建術を受けたが請求項1に記載の医薬組成物が投与されていない比較対象に対して、前記医薬組成物が投与された対象において減少する、請求項1に記載の医薬組成物。
- 血行再建術後6ヶ月以内の主要な有害心血管事象、死亡、心臓死、または鬱血性心不全の発生の発生率が、血行再建術を受けたが請求項1に記載の医薬組成物が投与されていない比較対象に対して、前記医薬組成物が投与された対象において減少する、請求項1に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29169909P | 2009-12-31 | 2009-12-31 | |
US61/291,699 | 2009-12-31 | ||
US36313810P | 2010-07-09 | 2010-07-09 | |
US61/363,138 | 2010-07-09 | ||
PCT/US2010/062538 WO2011082324A1 (en) | 2009-12-31 | 2010-12-30 | Methods for the prevention or treatment of vessel occlusion injury |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015104447A Division JP2015147810A (ja) | 2009-12-31 | 2015-05-22 | 血管閉塞傷害の予防または治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013516425A JP2013516425A (ja) | 2013-05-13 |
JP2013516425A5 true JP2013516425A5 (ja) | 2014-02-20 |
Family
ID=44226816
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012547305A Pending JP2013516425A (ja) | 2009-12-31 | 2010-12-30 | 血管閉塞傷害の予防または治療方法 |
JP2015104447A Pending JP2015147810A (ja) | 2009-12-31 | 2015-05-22 | 血管閉塞傷害の予防または治療方法 |
JP2016205764A Pending JP2017025093A (ja) | 2009-12-31 | 2016-10-20 | 血管閉塞傷害の予防または治療方法 |
JP2018025914A Pending JP2018087225A (ja) | 2009-12-31 | 2018-02-16 | 血管閉塞傷害の予防または治療方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015104447A Pending JP2015147810A (ja) | 2009-12-31 | 2015-05-22 | 血管閉塞傷害の予防または治療方法 |
JP2016205764A Pending JP2017025093A (ja) | 2009-12-31 | 2016-10-20 | 血管閉塞傷害の予防または治療方法 |
JP2018025914A Pending JP2018087225A (ja) | 2009-12-31 | 2018-02-16 | 血管閉塞傷害の予防または治療方法 |
Country Status (7)
Country | Link |
---|---|
US (7) | US20130195837A1 (ja) |
EP (5) | EP3269380A1 (ja) |
JP (4) | JP2013516425A (ja) |
CN (2) | CN102791280A (ja) |
AU (4) | AU2010339410A1 (ja) |
CA (1) | CA2786280A1 (ja) |
WO (1) | WO2011082324A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8697657B2 (en) * | 2010-03-15 | 2014-04-15 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
JP6319738B2 (ja) * | 2010-07-09 | 2018-05-09 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 虚血/再灌流障害に続くノーリフローの予防又は処置方法 |
AU2012315586B2 (en) | 2011-09-29 | 2017-07-20 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
CN107312066A (zh) * | 2011-12-09 | 2017-11-03 | 康德生物医疗技术公司 | 芳香族阳离子肽及其用途 |
US9636378B2 (en) * | 2012-03-30 | 2017-05-02 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment neuropathy |
PE20151434A1 (es) * | 2012-10-22 | 2015-10-16 | Stealth Peptides Int Inc | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo |
JP6839490B2 (ja) | 2013-03-01 | 2021-03-10 | ステルス バイオセラピューティックス コープ | ミトコンドリア疾患の治療のための方法 |
JP6518197B2 (ja) | 2013-03-01 | 2019-05-22 | ステルス バイオセラピューティックス コープ | バース症候群の予防または治療のための方法及び組成物 |
JP2016522196A (ja) * | 2013-05-14 | 2016-07-28 | ステルス バイオセラピューティックス コープ | 左室リモデリングの予防または治療のための方法 |
CA2916486A1 (en) * | 2013-06-26 | 2015-01-22 | Stealth Biotherapeutics Corp | Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction |
US10047395B2 (en) | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
WO2016004441A1 (en) * | 2014-07-03 | 2016-01-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of acute myocardial infarction injury |
EP3903802A1 (en) * | 2014-08-21 | 2021-11-03 | Stealth Biotherapeutics Corp | Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome |
US11548913B2 (en) * | 2015-12-31 | 2023-01-10 | Stealth Biotherapeutics Inc. | Therapeutic compositions including peptides and uses thereof |
WO2017156403A1 (en) * | 2016-03-11 | 2017-09-14 | Stealth Biotherapeutics | Crystalline salt forms |
US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
ES2942631T3 (es) * | 2017-12-15 | 2023-06-05 | Stealth Biotherapeutics Inc | Péptidos dirigidos a mitocondrias |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
ES2436011T3 (es) * | 2003-02-04 | 2013-12-26 | Cornell Research Foundation, Inc. | Métodos para prevenir la transición de la permeabilidad mitocondrial |
RU2376028C2 (ru) * | 2004-01-23 | 2009-12-20 | Корнелл Рисеч Фаундейшн, Инк. | Способ уменьшения окислительного повреждения (варианты) |
KR20140106761A (ko) * | 2005-09-16 | 2014-09-03 | 코넬 리서치 화운데이션,인크. | Cd36 발현을 감소시키는 방법 |
DK2262520T3 (en) * | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
US8697657B2 (en) * | 2010-03-15 | 2014-04-15 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
-
2010
- 2010-12-30 JP JP2012547305A patent/JP2013516425A/ja active Pending
- 2010-12-30 EP EP17169757.6A patent/EP3269380A1/en not_active Withdrawn
- 2010-12-30 CN CN201080065018XA patent/CN102791280A/zh active Pending
- 2010-12-30 CN CN201410010496.0A patent/CN103751763A/zh active Pending
- 2010-12-30 AU AU2010339410A patent/AU2010339410A1/en not_active Abandoned
- 2010-12-30 EP EP18183533.1A patent/EP3446698A1/en not_active Withdrawn
- 2010-12-30 EP EP10841732.0A patent/EP2519248A4/en not_active Withdrawn
- 2010-12-30 CA CA2786280A patent/CA2786280A1/en not_active Abandoned
- 2010-12-30 WO PCT/US2010/062538 patent/WO2011082324A1/en active Application Filing
- 2010-12-30 US US13/519,780 patent/US20130195837A1/en not_active Abandoned
- 2010-12-30 EP EP14197463.4A patent/EP2910250A1/en not_active Withdrawn
- 2010-12-30 EP EP16157727.5A patent/EP3090754A1/en not_active Withdrawn
-
2014
- 2014-01-07 US US14/149,606 patent/US20140341879A1/en not_active Abandoned
-
2015
- 2015-03-06 US US14/640,633 patent/US20160030501A1/en not_active Abandoned
- 2015-05-22 JP JP2015104447A patent/JP2015147810A/ja active Pending
- 2015-10-12 AU AU2015242952A patent/AU2015242952A1/en not_active Abandoned
-
2016
- 2016-05-26 US US15/165,139 patent/US20170100451A1/en not_active Abandoned
- 2016-10-20 JP JP2016205764A patent/JP2017025093A/ja active Pending
-
2017
- 2017-05-31 AU AU2017203662A patent/AU2017203662A1/en not_active Abandoned
- 2017-09-27 US US15/716,644 patent/US20180228864A1/en not_active Abandoned
-
2018
- 2018-02-16 JP JP2018025914A patent/JP2018087225A/ja active Pending
- 2018-12-05 US US16/211,125 patent/US20190336566A1/en not_active Abandoned
-
2019
- 2019-02-07 AU AU2019200823A patent/AU2019200823A1/en not_active Abandoned
-
2020
- 2020-02-28 US US16/804,900 patent/US20210023160A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013516425A5 (ja) | ||
JP2017165772A5 (ja) | ||
Meneveau et al. | Management of unsuccessful thrombolysis in acute massive pulmonary embolism | |
Napodano et al. | Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction | |
Oprea et al. | Perioperative management of antiplatelet therapy | |
JP2016172781A5 (ja) | ||
Ogawa et al. | Antithrombotic Therapy in Atrial Fibrillation–Evaluation and Positioning of New Oral Anticoagulant Agents– | |
JP2013531682A5 (ja) | ||
Tang et al. | Effect of delayed vs immediate stent implantation on myocardial perfusion and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention with thrombus aspiration | |
JP2009521472A (ja) | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト | |
JP4140981B2 (ja) | 再狭窄症及び動脈硬化症治療薬 | |
Bates | Reperfusion therapy in inferior myocardial infarction | |
Ronner et al. | Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study | |
Urschel Jr et al. | Thoracic outlet syndromes | |
Orrego et al. | Distal protection in native coronary arteries during primary angioplasty in acute myocardial infarction: Single‐center experience | |
Nguyen et al. | Prevention and treatment of atherothrombosis: Potential impact of nanotechnology | |
Zasada et al. | Patient with atrial fibrillation and myocardial infarction due to coronary artery embolism treated with thrombus aspiration | |
Topol et al. | Massive hemorrhagic myocardial infarction after coronary thrombolysis | |
US20230398266A1 (en) | Therapeutic agent for use in local treatment of inflammation associated with atherosclerosis and/or a thrombotic state | |
Kishi et al. | Percutaneous coronary arterial thrombectomy for acute myocardial infarction reduces no-reflow phenomenon and protects against left ventricular remodeling related to the proximal left anterior descending and right coronary artery | |
AU2003234596B2 (en) | A method for inhibiting platelet aggregation | |
Smith et al. | Recent advances in primary percutaneous intervention for acute myocardial infarction | |
Hokimoto et al. | Initial and mid-term outcomes of pulse infusion thrombolysis using a unique pump system and stent placement for deep vein thrombosis | |
Morteza Safi et al. | The comparison of intracoronary versus intravenous eptifibatide administration during primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction | |
JP5589838B2 (ja) | 血管性疾患の予防剤及び/又は治療剤 |